Wordt geladen...
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...
Bewaard in:
| Gepubliceerd in: | Front Med (Lausanne) |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6930172/ https://ncbi.nlm.nih.gov/pubmed/31921871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2019.00295 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|